Research findings differentiate prostate cancer tumors into five different types
the ONA take:
Determining the appropriate course of treatment for prostate cancer can be a challenge for clinicians.
The disease can be slow growing and never cause a problem for a man or it can be an aggressive disease requiring immediate treatment.
Scientists at Cancer Research UK recently found that prostate cancer has five distinct types, and they also found a way to determine which type of tumor a patient has.
The researchers looked for abnormal chromosomes and measured the activity of 100 genes linked to prostate cancer in healthy and cancerous tissue samples from more than 250 men. They were able to group the tumors into five different types, each with its own genetic fingerprint.
The next step is to confirm their findings in larger studies that further explore how each specific type behaves.
However, the researchers report that their findings could lead to better understanding of the disease and more effective treatment for patients who have aggressive disease.
Prostate cancer has five distinct types, with different ways to determine which type of tumor a patient has.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Patients With Urologic Cancer Need Psycho-oncologic Support to Manage High Stress
- E-cigarettes and Replacement Nicotine Therapy Safer Than Tobacco Use
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Patients Undergoing Multiple Systemic Therapies for Metastatic Prostate Cancer Expect a Cure
- FDA Grants Priority Review to Ceritinib for First-line Treatment of ALK+ NSCLC
- Overall Health Worse in African American Men Undergoing Active Surveillance For Prostate Cancer
- Clinical Benefit of Simtuzumab Inconsistent for Myelofibrosis
- Follow-up Rates in Active Surveillance for Prostate Cancer Higher in University-Based vs Safety-Net Hospitals
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|